Lizheng Shi trained as a pharmacist (BS in pharmacy 1992, MS in pharmacy 1994) through Shanghai Medical University and Peking Union Medical College, respectively. He has also trained as an economist (MA in economics 1998, PhD in pharmaceutical economics and policy 2001) through the University of Southern California.
Shi is the Regents professor and vice chair in the department of global health policy and management, and he serves as clinical faculty in departments of medicine (endocrinology) and psychiatry.
Shi is the director for Health Systems Analytics Research Center (HSARC). He is a member of editorial board for Pharmacoeconomics.
Shi’s current research interest includes health technology assessment and health care quality, access and economics. He is also interested in pharmacoepidemilogy with a focus on safety issues in medication treatment and health informatics to improve quality and safety of patient care.
Shi has served as principal investigators (PI) and co-PI for more than 30 research grants and contracts from NIH, AHRQ, PCORI, and other public and private funding sources.
Areas of Expertise (5)
health technology assessment
University of Southern California: PhD, Pharmaceutical Economics and Policy
University of Southern California: M.A., Economics
Peking Union Medical College: M.S., Pharmacy
Shanghai Medical University: B.S., Pharmacy
Media Appearances (1)
Medicare penalizes N.O. hospitals for safety lapses, readmissions
Louisiana Weekly online
Hospital safety has improved over the last several years in the state and across the nation, Lizheng Shi, director of Tulane University’s Health Systems Analytics Research Center, said last week. “And yet approximately a third of Louisiana’s hospitals, large and small, have been penalized by Medicare in this fiscal year,” he said. “Since its inception, targeting with penalties has generated lots of dialogue among senior hospital executives about front-line patient care and how to make improvements using Louisiana’s best practices.”
2018 Middle East respiratory syndrome coronavirus (MERS-CoV) has represented a human health threat since 2012. Although several MERS-related CoVs that belong to the same species as MERS-CoV have been identified from bats, they do not use the MERS-CoV receptor, dipeptidyl peptidase 4 (DPP4). Here, we screened 1,059 bat samples from at least 30 bat species collected in different regions in south China and identified 89 strains of lineage C betacoronaviruses, including Tylonycteris pachypus coronavirus HKU4, Pipistrellus pipistrellus coronavirus HKU5, and MERS-related CoVs.